

Counting Hemangiomas Can Help Determine Risk

BY SHERRY BOSCHERT

Counting hemangiomas is one way to identify higher risk when managing infantile hemangiomas, which are tremendously heterogeneous, according to Dr. Ilona J. Frieden.

For example, having more than five infantile hemangiomas increases the risk of having liver hemangiomas, she explained at a women's and pediatric dermatology seminar sponsored by Skin Disease Education Foundation (SDEF).

Infantile hemangiomas reach 80% of their maximum size at a mean age of 3 months, a study of more than 1,000 patients found (*Pediatrics* 2008;122:360-7). By 5 months, 80% have finished growing, highlighting the importance of early referral to a specialist.

Hemangiomas in the periocular region, airway, or liver can cause some of the greatest potential medical morbidi-

ties, and parents lack the context for interpreting the information they find, so it is important to be proactive and discuss this with them, she advised.

Dr. Frieden is a consultant to Pierre Fabre Laboratories, which is conducting trials of propranolol as a treatment for hemangiomas. SDEF and this news organization are owned by Elsevier. ■



Ulceration is more likely in hemangiomas that are segmental, and in those that occur on the lower lip, neck, and anogenital area.

COURTESY DR. ILONA J. FRIEDEN



Having more than five infantile hemangiomas increases the risk of having liver hemangiomas.

DR. FRIEDEN

ties, noted Dr. Frieden, director of pediatric dermatology at the University of California, San Francisco. The risk of permanent disfigurement is a common reason for treatment, and this is particularly true for hemangiomas involving the central face, nasal tip, ear, glabella, cheek, and perioral area.

Localized hemangiomas—those that are spatially confined and often appear to arise from a central focal point—are of less concern than segmental ones, though localized lesions can cause problems if they grow large enough.

Segmental hemangiomas—those that affect a broad anatomic region or a recognized developmental unit such as an entire ear or that seem dermatomal—are significantly more likely to develop complications and to need treatment, compared with localized lesions, she noted.

Residual skin changes are more likely if the infantile hemangioma is pedunculated or there is a sharp drop-off or steep slope to the lesion. Thin plaques and lesions with a gradual slope to normal skin have a better prognosis.

Ulceration, which is the most common complication of hemangiomas, occurs at a median age of 4 months. It is more likely in hemangiomas that are segmental (33%, versus 7% localized), and in hemangiomas on the lower lip (30%), neck (25%), and anogenital area (50%), Dr. Frieden noted.

The tremendous heterogeneity of infantile hemangiomas can complicate parental peace of mind when a worried parent turns to the Internet for information. Internet postings tend to emphasize

For the multi-faceted challenges of mild to moderate rosacea

offering more
in one convenient package

Introducing
Finacea
(azelaic acid) Gel, 15%
plus

myfinacea.com – a website for patient support and education

Finacea is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.

Finacea is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. Finacea is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety—Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexion, these patients should be monitored for early signs of hypopigmentation.

Please see brief summary of Prescribing Information on following page.